CAJ | 학술논문

神经病理性疼痛是一种常见的慢性疼痛疾病，发病机制复杂且临床治疗效果欠佳。最近研究表明， N-甲基-D-天冬氨酸受体/突触后致密蛋白95/神经元型一氧化氮合酶（NMDAR/PSD-95/nNOS）复合物在神经病理性疼痛中发挥重要作用。研究发现，如果不直接抑制NMDAR或nNOS，选择性阻断NMDAR/PSD-95或者nNOS/PSD-95的相互作用，可以在不影响NMDAR和nNOS生理功能的前提下抑制神经病理性疼痛中NO的病理性释放，可能获得没有明显副作用的安全有效的神经病理性疼痛的治疗药物。故本文对NMDAR/PSD-95/nNOS复合物在神经病理性疼痛中的研究进展进行综述。
신경병이성동통시일충상견적만성동통질병，발병궤제복잡차림상치료효과흠가。최근연구표명， N-갑기-D-천동안산수체/돌촉후치밀단백95/신경원형일양화담합매（NMDAR/PSD-95/nNOS）복합물재신경병이성동통중발휘중요작용。연구발현，여과불직접억제NMDAR혹nNOS，선택성조단NMDAR/PSD-95혹자nNOS/PSD-95적상호작용，가이재불영향NMDAR화nNOS생리공능적전제하억제신경병이성동통중NO적병이성석방，가능획득몰유명현부작용적안전유효적신경병이성동통적치료약물。고본문대NMDAR/PSD-95/nNOS복합물재신경병이성동통중적연구진전진행종술。
Neuropathic pain is a common chronic pain disease, with complex pathogenesis and inefficient clinical treatment. Recent studies have shown that N-methyl-D-aspartic acid receptor/postsynaptic density protein 95/neuronal nitric oxide synthase (NMDAR/PSD-95/nNOS) complex plays an important role in neuropathic pain. Studies found that it may obtain safe and effective drug for treatment of neuropathic pain with no obvious side effects, if a drug do not inhibit the NMDAR or nNOS directly but selectively disrupt the interaction of NMDAR/PSD-95 or PSD-95/nNOS, which can reduce the release of NO in neuropathic pain without affecting the NMDAR and nNOS functions. Therefore, the research progresses of NMDAR/PSD-95/nNOS complex in neuropathic pain are summarized in this paper.